HYHaoran Yu

Haoran Yu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Haoran Yu has a total of 20 co-authors. Here are the top co-authors by number of shared publications:

  • Changming Wang

    Department of Orthopaedics, The Second Affiliated Hospital of Anhui Medical University, Hefei 230601, China; Institute of Orthopaedics, Research Center for Translational Medicine, The Second Affiliated Hospital of Anhui Medical University, Hefei 230601, China

    3 shared publications
  • Chen Wang

    Department of Orthopaedics, The Second Affiliated Hospital of Anhui Medical University, Hefei 230601, China; Institute of Orthopaedics, Research Center for Translational Medicine, The Second Affiliated Hospital of Anhui Medical University, Hefei 230601, China

    3 shared publications
  • Junyan He

    Department of Orthopaedics, The Second Affiliated Hospital of Anhui Medical University, Hefei 230601, China; Institute of Orthopaedics, Research Center for Translational Medicine, The Second Affiliated Hospital of Anhui Medical University, Hefei 230601, China

    3 shared publications
  • Wendan Cheng

    Department of Orthopedics, The Second Affiliated Hospital of Anhui Medical University, Hefei, China

    3 shared publications
  • Zhongyao Hu

    Department of Orthopaedics, The Second Affiliated Hospital of Anhui Medical University, Hefei 230601, China; Institute of Orthopaedics, Research Center for Translational Medicine, The Second Affiliated Hospital of Anhui Medical University, Hefei 230601, China

    3 shared publications
  • Chun Zhang

    Department of Orthopedics, The Second Affiliated Hospital of Anhui Medical University, Hefei, China

    2 shared publications

Latest Publications

  • CXCL8 and GZMB genes promote cartilaginous and synovial lesion formation via NF-κB and MAPK signaling pathways in Kaschin–Beck disease

    by Dechao Cai, Zhongyao Hu, Yakun Zhu, Xiao Ma, Changming Wang, Chen Wang, Ashuai Bian, Haotian Zhang, Junyan He, CiRen LunZhu, et al.


  • Open Access

    The comparative efficacy of L-glutamine, celecoxib, and glucosamine sulfate in osteoarthritis management

    by Zhongyao Hu, Changming Wang, Chen Wang, Junyan He, Yiqun Yan, Zelin Xu, Yangmang Yu, Ya Yu, Huan Cheng, Lei Liu, et al.

    To explore the therapeutic efficacy of L-glutamine (L-Gln) on pathological progression and clinical symptoms of osteoarthritis (OA), and compare with glucosamine sulfate (GS), and celecoxib (CXB). Rats were administered sodium chloride, L-Gln, GS, or CXB via gavage for eight weeks starting from the fifth week after sham operation or Anterior Cruciate Ligament Transection (ACLT) + Medial Meniscectomy (MMx). Then the severity of knee OA in rats was evaluated by serological analysis, histological examination and imaging examination. In addition, patients with mild primary OA were administered L-Gln, GS, or CXB orally for 12 weeks in accordance with the randomization principle. The efficacy end points were the change from baseline to week 24 in the pain and physical function subscale scores of the Western Ontario and McMaster Universities OA Index (WOMAC), and Lequesne score. Treatment with L-Gln alleviated the increased concentration of serum cartilage degradation markers caused by OA in rats. Histological tests showed improvement in knee joint cartilage destruction after treatment. Three-dimensional CT scans and reconstructions revealed a reduction in osteophyte formation and subchondral bone loss. L-glutamine performed as well as or better than glucosamine sulfate and celecoxib in all comparative measures among the three treatment groups. In clinical trials, the WOMAC pain and physical function subscale scores, as well as the Lequesne score, decreased from baseline in all three patient groups during follow-up, with no significant differences observed between the groups. Our research indicates that L-Gln is comparable to GS and CXB in improving the pathological progression and clinical efficacy of OA, which makes it a promising drug for the treatment of osteoarthritis.


  • Open Access

    The Efficacy of L-glutamine in Osteoarthritis:a comparative analysis with celecoxib and glucosamine sulfate.

    by Wendan Cheng, Zhongyao Hu, Changming Wang, Chen Wang, Junyan He, Yiqun Yan, Zelin Xu, Yangmang Yu, Chun Zhang, Haoran Yu, et al.

    Objective: to explore the therapeutic efficacy of L-glutamine (L-Gln) in osteoarthritis(OA), and compare with glucosamine sulfate (GS), and celecoxib (CXB). Methods: Male SD rats were administered sodium chloride, L-Gln, GS, or CXB via gavage for eight weeks starting in the fifth week after operation. Then the severity of knee OA in rats was evaluated by serological analysis, histological examination and imaging examination. Patients with mild OA were administered L-Gln, GS, or CXB orally for 12 weeks in accordance with the randomization principle. Efficacy end points were the change from baseline to week 24 in the pain and physical function subscale scores of the Western Ontario and McMaster Universities OA Index (WOMAC), and Lequesne score. Results: The treatment with L-Gln and two other drugs alleviated the increased concentration of serum cartilage degradation markers, cartilage destruction, osteophyte formation, and loss of subchondral bone mass caused by OA in rats. During follow-up, the WOMAC pain and physical function subscale scores and Lequesne score of all three groups of patients decreased from baseline and exceeded the minimum clinical difference. The results indicate that the therapeutic effect of L-Gln is comparable to the other two drugs, and in some indicators, it may even be superior to them. Conclusion: Our research indicates that L-Gln is comparable to GS and CXB in improving the pathological progression and clinical efficacy of OA. However, L-Gln has a lower occurrence of gastrointestinal adverse reactions and effectively alleviates knee joint pain in OA patients who are unresponsive to NSAIDs and GS. This makes it a promising drug for the treatment of osteoarthritis.